{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:16:39Z","timestamp":1762323399196},"reference-count":125,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2011,2,28]]},"DOI":"10.2217\/fon.10.174","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T05:34:52Z","timestamp":1298525692000},"page":"201-218","source":"Crossref","is-referenced-by-count":4,"title":["Nilotinib: Evaluation and Analysis of Its Role in Chronic Myeloid Leukemia"],"prefix":"10.1080","volume":"7","author":[{"given":"Paula","family":"Garland","sequence":"first","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"e_1_3_2_2_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/306277a0"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1569"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.s.001"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-038943"},{"key":"e_1_3_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"e_1_3_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_3_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.014"},{"key":"e_1_3_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_3_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.10.001"},{"key":"e_1_3_2_2_12_1","doi-asserted-by":"crossref","unstructured":"Bixby D TalpazM: Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.Hematology461\u2013476 (2009).","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"e_1_3_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_3_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-066936"},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.3.1014"},{"key":"e_1_3_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1068"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70379-0"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017178"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_3_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_3_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_3_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_3_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.228"},{"key":"e_1_3_2_2_28_1","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib.","volume":"112","author":"Cortes J","year":"2008","unstructured":"Cortes J , KantarijanH, KimD: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib.Blood112, Abstract 1098 (2008).","journal-title":"Blood"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.032"},{"key":"e_1_3_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.79"},{"key":"e_1_3_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25079"},{"key":"e_1_3_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.05.004"},{"key":"e_1_3_2_2_33_1","first-page":"233","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia.","volume":"2","author":"Fava C","year":"2009","unstructured":"Fava C , KantarjianH, CortesJ, JabbourE: Development and targeted use of nilotinib in chronic myeloid leukemia.Drug Des. Devel.Ther.2, 233\u2013243 (2009).","journal-title":"Drug Des. Devel.Ther."},{"key":"e_1_3_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21299"},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.3365.3365"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0972"},{"key":"e_1_3_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"key":"e_1_3_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.643.643"},{"key":"e_1_3_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8853"},{"key":"e_1_3_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_3_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.208"},{"key":"e_1_3_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100268"},{"key":"e_1_3_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.166"},{"key":"e_1_3_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404638"},{"key":"e_1_3_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.04.002"},{"key":"e_1_3_2_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00383.x"},{"key":"e_1_3_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"e_1_3_2_2_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009336137"},{"key":"e_1_3_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010367428"},{"key":"e_1_3_2_2_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009346061"},{"key":"e_1_3_2_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.016"},{"key":"e_1_3_2_2_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0327-0"},{"key":"e_1_3_2_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_3_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-67"},{"key":"e_1_3_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1129.1129"},{"issue":"15","key":"e_1_3_2_2_58_1","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a Phase II study.","volume":"27","author":"Le Coutre PD","year":"2009","unstructured":"Le Coutre PD , GilesF, HochhausAet al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a Phase II study.J. Clin. Oncol.27(Suppl. 15), Abstract 7057 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_2_59_1","article-title":"Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib.","volume":"20","author":"Giles FJ","year":"2008","unstructured":"Giles FJ , LarsonRA, KantarjianHMet al.: Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib.J. Clin. Oncol.20(Suppl.), Abstract 7017 (2008).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_2_60_1","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): updated safety analysis.","volume":"20","author":"Nicolini FE","year":"2008","unstructured":"Nicolini FE , AlimenaG, Al-AliHet al.: Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): updated safety analysis.J. Clin. Oncol.20(Suppl.), Abstract 7059 (2008).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_2_61_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2201.2201","article-title":"Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or \u2013intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study.","volume":"114","author":"Nicolini F","year":"2009","unstructured":"Nicolini F , KimD, CeglarekBet al.: Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or \u2013intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study.Blood114, Abstract 2201 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_2_62_1","article-title":"Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study.","volume":"114","author":"le Coutre P","year":"2009","unstructured":"le Coutre P , AlimenaG, KimDet al.: Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study.Blood114, Abstract 3286 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.110"},{"key":"e_1_3_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291922"},{"key":"e_1_3_2_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"issue":"15","key":"e_1_3_2_2_66_1","article-title":"Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a Phase II trial of the GIMEMA CML WP.","volume":"27","author":"Martinelli G","year":"2009","unstructured":"Martinelli G , CastagnettiF, PoerioAet al.: Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a Phase II trial of the GIMEMA CML WP.J. Clin. Oncol.27(Suppl. 15), Abstract 7074 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_2_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_3_2_2_68_1","doi-asserted-by":"crossref","unstructured":"Rosti GR CastagnettiF PalandriFet al.: Nilotinib 400 mg bid in early chronic phase PH chronic myeloid leukemia: results at 2 years of a Phase II trial.Presented at:15th Congress of the European Hematology AssociationBarcelona Spain 10\u201313 June 2010.","DOI":"10.1200\/jco.2010.28.15_suppl.6515"},{"key":"e_1_3_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3294.3294"},{"key":"e_1_3_2_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1"},{"key":"e_1_3_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.339.339"},{"key":"e_1_3_2_2_73_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.337.337","article-title":"24 months update of the TOPS Study: a Phase III, randomized, open-label study of 400 mg\/d (SD-IM) versus 800 mg\/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP).","volume":"114","author":"Baccarani M","year":"2009","unstructured":"Baccarani M , DrukerB, CortesJet al.: 24 months update of the TOPS Study: a Phase III, randomized, open-label study of 400 mg\/d (SD-IM) versus 800 mg\/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP).Blood114, Abstract 337 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_2_74_1","unstructured":"Hochhaus A LoboC PasquiniRet al.: Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year.Presented at:15th Congress of the European Hematology AssociationBarcelona Spain 10\u201313 June 2010."},{"key":"e_1_3_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_3_2_2_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.183.183"},{"key":"e_1_3_2_2_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-026377"},{"key":"e_1_3_2_2_78_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004423"},{"key":"e_1_3_2_2_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.242"},{"key":"e_1_3_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4639"},{"key":"e_1_3_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1008"},{"issue":"1","key":"e_1_3_2_2_82_1","first-page":"56","article-title":"Efficacy of subcutaneous homoharringtonine in chronic myeloid leukemia (CML) patients resistant to tyrosine kinase inhibitors (TKI) and harboring a BCR\u2013ABL mutation.","volume":"93","author":"Marin D","year":"2008","unstructured":"Marin D , MaloiselF, LegrosL, NicoliniFE: Efficacy of subcutaneous homoharringtonine in chronic myeloid leukemia (CML) patients resistant to tyrosine kinase inhibitors (TKI) and harboring a BCR\u2013ABL mutation.Haematologica93(Suppl. 1), 56 Abstract 0139 (2008).","journal-title":"Haematologica"},{"key":"e_1_3_2_2_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094508"},{"key":"e_1_3_2_2_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3239.3239"},{"key":"e_1_3_2_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1030.1030"},{"key":"e_1_3_2_2_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113175"},{"key":"e_1_3_2_2_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-01222-8_14"},{"key":"e_1_3_2_2_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.04.012"},{"key":"e_1_3_2_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_3_2_2_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.643.643"},{"key":"e_1_3_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1932"},{"key":"e_1_3_2_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.012"},{"key":"e_1_3_2_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.04.005"},{"key":"e_1_3_2_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.04.030"},{"key":"e_1_3_2_2_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0542"},{"key":"e_1_3_2_2_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22920"},{"key":"e_1_3_2_2_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_3_2_2_98_1","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes.","volume":"114","author":"Hagop M","year":"2009","unstructured":"Hagop M , KantarijanH, GilesFet al.: Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes.Blood114 Abstract 1129 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_2_99_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010496"},{"key":"e_1_3_2_2_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404827"},{"key":"e_1_3_2_2_101_1","article-title":"Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the ENACT (Expanding Nilotinib Access in Clinical Trials) study.","volume":"114","author":"le Coutre PD","year":"2009","unstructured":"le Coutre PD , CeglarekB, TurkinaAet al.: Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the ENACT (Expanding Nilotinib Access in Clinical Trials) study.Blood114, Abstract 2960 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_2_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.2960.2960"},{"key":"e_1_3_2_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.01.024"},{"key":"e_1_3_2_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.015"},{"key":"e_1_3_2_2_105_1","doi-asserted-by":"crossref","unstructured":"Jabbour E HochhausA le CoutrePet\u00a0al.: Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP).J. Clin. Oncol.Abstract 7063 (2008).","DOI":"10.1200\/jco.2008.26.15_suppl.7063"},{"issue":"1","key":"e_1_3_2_2_106_1","first-page":"56","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP).","volume":"93","author":"Hochhaus A","year":"2008","unstructured":"Hochhaus A , KantarijanH, BaccaraniMet al.: Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP).Haematologica93(Suppl. 1) 56, Abstract 0141 (2008).","journal-title":"Haematologica"},{"key":"e_1_3_2_2_107_1","unstructured":"Squires MS ReuleM CurryJet al.: AT9283 a potent inhibitor of bcr\u2013abl T315I is active in CML models. Presented at:2008 Annual Meeting of American Association of Cancer ResearchCA USA 12\u201316 April 2008 (Abstract 2820)."},{"key":"e_1_3_2_2_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.576.576"},{"key":"e_1_3_2_2_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-010-0045-y"},{"key":"e_1_3_2_2_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_3_2_2_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701705941"},{"key":"e_1_3_2_2_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.161"},{"key":"e_1_3_2_2_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144071"},{"key":"e_1_3_2_2_114_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.006486"},{"key":"e_1_3_2_2_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108241"},{"key":"e_1_3_2_3_2_1","unstructured":"Newcastle University Trial Group. SPIRIT II Trial www.leukemia-net.org (2010)."},{"key":"e_1_3_2_3_3_1","unstructured":"Novartis Oncology www.tasigna.com"},{"key":"e_1_3_2_3_4_1","unstructured":"EMEA nilotinib product specification data Scientific discussion www.emea.europa.eu"},{"key":"e_1_3_2_3_5_1","unstructured":"Imatinib versus nilotinib in adult patients with a suboptimal cytogenetic response with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) (ENEST) NCT00519090 (2010) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00519090?term=NCT00519090&rank=1"},{"key":"e_1_3_2_3_6_1","unstructured":"Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With Suboptimal Response (SENSOR)NCT01043874 (2010) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01043874?term=NCT01043874&rank=1N"},{"key":"e_1_3_2_3_7_1","unstructured":"Suboptimal Study Comparing Nilotinib and Imatinib (LASOR) NCT00802841 (2010) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00802841?term=LASOR&rank=1"},{"key":"e_1_3_2_3_8_1","unstructured":"FDA nilotinib full prescribing information. Revised June 2010 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf"},{"key":"e_1_3_2_3_9_1","unstructured":"European Medicines Agency. Summary of opinion \u2013 Tasigna. EMA\/CHMP\/462567\/2010 www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000798\/WC500097019.pdf"},{"key":"e_1_3_2_3_10_1","unstructured":"National Institute of Clinical Excellence (NICE). Appraisal Consultation Document Imatinib-intolerant chronic myeloid leukaemia \u2013 dasatinib and nilotinib (2009) www.nice.org.uk\/guidance November"},{"key":"e_1_3_2_3_11_1","unstructured":"Hammersmith Hospital\/Southampton Hospital CML vaccine trial. Trial design in process (2010) www.eme.ac.uk\/projectfiles\/089924info.pdf"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:11Z","timestamp":1719125111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2,28]]}},"alternative-id":["10.2217\/fon.10.174"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.174","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]}}}